Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.34 |
| ▸ | PRKDC | P78527 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TRHR | P34981 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853447 | 0.83 | CPB2 (0.46) | PIK3CGPIK3CAMTNR1ACPB2PRKDC | |
| SCHEMBL13853448 | 0.81 | CPB2 (0.51) | PIK3CGPIK3CAMTNR1ACPB2PRKDC | |
| SCHEMBL13870511 | 0.80 | CPB2 (0.50) | PIK3CGPIK3CAMTNR1ACPB2PRKDC | |
| SCHEMBL13870508 | 0.79 | PIK3CG (0.36) | PIK3CGPIK3CAMTNR1ACPB2PRKDC | |
| SCHEMBL3202060 | 0.70 | CYP2C9 (0.50) | CPB2CYP2C9TRHRCPB1 | |
| Hydrochloric Acid SCHEMBL4079400 | 0.69 | TDP1 (0.51) | CPB2CYP2C9TRHRCPB1 | |
| Hydrochloric Acid SCHEMBL4079392 | 0.69 | TDP1 (0.51) | CPB2CYP2C9TRHRCPB1 | |
| SCHEMBL12662747 | 0.69 | CPB2 (0.48) | PIK3CGPIK3CAMTNR1ACPB2CPB1 | |
| SCHEMBL2051187 | 0.68 | TRHR (0.31) | TRHR | |
| SCHEMBL4079394 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517995-B2 | Thiazolyl-dihydro-cyclopentapyrazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | REN, ROR1, RORB | PIK3CG 4794/4885PIK3CA 4258/4885MTNR1A 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.